<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011372</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54828-203</org_study_id>
    <nct_id>NCT03011372</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)</brief_title>
  <official_title>A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828)
      in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1
      rearrangement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants who achieve Complete Response (CR) based on response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement</measure>
    <time_frame>: Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieve response, defined as a best response of CR or PR, as determined by investigator assessment according to the response criteria</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieve a complete cytogenetic response (CCyR) as assessed by local analysis and investigator evaluation</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieve a partial cytogenetic response (PCyR) as assessed by local analysis and investigator evaluation</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR, defined as the time from first assessment of CR to the earlier of disease progression or death due to any cause</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response, defined as the time from first assessment of CR or PR to the earlier of disease progression or death due to any cause</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the date of first study drug dose until the date of disease progression or until death due to any cause, whichever is earlier, assessed up to approximately 24 months.</time_frame>
    <description>PFS is defined as the time from the first date of taking study drug until the date of disease progression, as measured by response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement, or until death due to any cause, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first study drug dose until death due to any cause, assessed up to approximately 24 months.</time_frame>
    <description>Overall survival is defined as the time from the first day of taking study drug until death due to any cause. Subjects without death observed at the time of the analysis will be censored at last date known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by frequency, duration, and severity of adverse events</measure>
    <time_frame>From baseline through 30-35 days after end of treatment, up to 7 months per individual subject</time_frame>
    <description>A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>MPN (Myeloproliferative Neoplasms)</condition>
  <arm_group>
    <arm_group_label>Pemigatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemigatinib</intervention_name>
    <description>Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
Participants will receive either the intermittent dose (as written) or continuous dosing.</description>
    <arm_group_label>Pemigatinib</arm_group_label>
    <other_name>INCB054828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1
             activation, based on standard diagnostic cytogenetic evaluation performed locally,
             before signing informed consent for this study.

          -  Eligible subjects must:

               -  Have relapsed after stem cell transplantation or after other disease modifying
                  therapy, OR

               -  Not be current candidates for stem cell transplantation or other disease
                  modifying therapies.

          -  Note: All relapsed/refractory subjects must have evidence of either cytogenetic or
             hematological disease and have no evidence of residual toxicity (eg, graft-versus-host
             disease requiring treatment).

          -  Life expectancy ≥ 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

        Exclusion Criteria:

          -  Prior receipt of a selective FGFR inhibitor.

          -  History and/or current evidence of ectopic mineralization/calcification, including but
             not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified
             lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.

          -  Current evidence of corneal disorder/keratopathy, including but not limited to
             bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and
             keratoconjunctivitis, as confirmed by ophthalmologic examination.

          -  Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5
             half-lives (whichever is shorter) before the first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterine Asatiani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Barva Baishakhi</last_name>
      <phone>626-218-9448</phone>
      <email>bbarva@coh.org</email>
    </contact>
    <investigator>
      <last_name>Haris Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Justin Abuel</last_name>
      <phone>650-723-1367</phone>
      <email>jabuel@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Gotlib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Shannon Gleason</last_name>
      <phone>404-778-4334</phone>
      <email>shannon.gleason@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Elliott Winton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Cancer Center - St. Francis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Melanie Coleman</last_name>
      <phone>317-528-7298</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Luke Akard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Karyn Gordon</last_name>
      <phone>314-362-0156</phone>
      <email>kdgordon@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Julian Danetiu</last_name>
      <phone>212-746-1204</phone>
      <email>jjd4001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Thinh Nguyen</last_name>
      <phone>713-745-4834</phone>
      <email>tqnguyen1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Srdan Verstovsek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Angela Plasser</last_name>
      <phone>+43 732 7677 4319</phone>
      <email>Angela.plasser@ordensklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Andreas Petzer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Kathrin Holzer</last_name>
      <phone>+43 1 9102185435</phone>
      <email>kathrin.holzer@wgkk.at</email>
    </contact>
    <investigator>
      <last_name>Thamer Sliwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iii Med. Abteilung Für Hämatologie Und Onkologie, Hanuscfhkrankenhaus</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Renate Schoder</last_name>
      <phone>+43 1 40400 812227</phone>
      <email>renate.schoder@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Heinz Gisslinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre - University of Toronto</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator Lorenz Yeung</last_name>
      <phone>416-634-7363</phone>
      <email>lorenz.yeung@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Dr Vikas Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Jérémy Monfray</last_name>
      <phone>+33 4 69 85 61 95</phone>
      <email>jeremy.monfray@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Franck-Emmanuel Nicolini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice, Hôpital L'Archet 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Irit Touitou</last_name>
      <phone>+33 4 92 03 90 87</phone>
      <email>touitou.i@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas Cluzeau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Souhil Allaoua</last_name>
      <phone>+33 1 42 38 54 42</phone>
      <email>souhil.allaoua@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Kiladjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopôle</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Amandine Virlojeux</last_name>
      <phone>+33 5 31 15 63 30</phone>
      <email>virlojeux.amandine@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Francoise Huguet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Sabrina Holst</last_name>
      <phone>+49 2 418 037 141</phone>
      <email>sholst@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Koschmieder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale) Klinik für Innere Medizin IV Onkologie/Hämatologie/Hämostaseologie Landeszentrum für Zell- und Gentherapie</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Karolin Hubert</last_name>
      <phone>+49 3 455 577260</phone>
      <email>karolin.hubert@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Haifa Kathrin Al-Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Klinik und Poliklinik für Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Marina Liebing</last_name>
      <phone>+49 3641 9396675</phone>
      <email>marina.liebing@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Hochhaus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Ann-Katrin Spintig</last_name>
      <phone>+49 (0) 34 197 13061</phone>
      <email>ann-katrin.spintig@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Uwe Platzbecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinischen Fakultät Mannheim der Universität Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Brigitte Simeu</last_name>
      <phone>+49 03641-9396675169</phone>
      <email>brigitte.simeu@umm.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Reiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. PAPA GIOVANNI XXIII (ex Ospedali Riuniti)</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Gaia Bonacina</last_name>
      <phone>+39 352 674657</phone>
      <email>ematosc@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Chiara Paoli</last_name>
      <phone>+39 55 7947688</phone>
      <email>chiara.paoli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Vannucchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center - Tokyo</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Lucia Brines</last_name>
      <phone>+34 96 197 35 83</phone>
      <email>luciabrinsi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Hernandez Boluda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitaetsspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Renata Bunter</last_name>
      <phone>+41 31 632 34 57</phone>
      <email>renata.buenter@ctu.unibe.ch</email>
    </contact>
    <investigator>
      <last_name>Gabriela Baerlocher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie - Zurich University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Julia Stickelberger</last_name>
      <phone>+41 442559565</phone>
      <email>julia.stickelberger@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Balabanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Trisha Enes</last_name>
      <phone>+44 2 07 18847188</phone>
      <email>trisha.enes@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Claire Harrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Sally Springett</last_name>
      <phone>+44 1 865 572 023</phone>
      <email>sally.springett@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adam Mead</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloid neoplasm</keyword>
  <keyword>fibroblast growth factor receptor inhibitor</keyword>
  <keyword>FGFR1 rearrangement</keyword>
  <keyword>8p11</keyword>
  <keyword>eosinophilia</keyword>
  <keyword>eosinophilic syndrome</keyword>
  <keyword>Lymphoid neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

